In addition, an analysis of immune checkpoints showed that FBLN5 levels were positively correlated with immune checkpoints and most carcinomas, such as lung adenocarcinoma (STES), transitional cell carcinoma of the bladder (BLCA), and lung squamous cell carcinoma (LUSC), which could guide effective immunotherapy for these tumors (Figure 7E). This evidence concerns the gene FBLN5 and carcinoma.